Media coverage about Stellar Biotechnologies (NASDAQ:SBOT) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stellar Biotechnologies earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.033949290348 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Stellar Biotechnologies (NASDAQ:SBOT) opened at $1.08 on Wednesday. Stellar Biotechnologies has a one year low of $1.05 and a one year high of $3.00.
WARNING: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/15/stellar-biotechnologies-sbot-receiving-somewhat-favorable-media-coverage-study-finds.html.
Stellar Biotechnologies Company Profile
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.